CZ VETERINARIA IS NEGOTIATING ASTRAZENECA PLANT PURCHASE
CZ Veterinaria aims to broaden its product range by producing human vaccines.
The Galician biopharmaceutical company, CZ Veterinaria, is currently negotiating acquisition of the AstraZeneca plant located in the Torneiros industrial estate in Porriño, on the market since late 2008. An auditor’s report is pending at present.
The veterinary company plans to use the new premises to produce vaccines for humans, which it will do through Biofabri, a new subsidiary company created in 2008.
CZ Veterinaria is the largest European manufacturer of vaccines against bluetongue disease. In 2008, the company supplied the German and Portuguese governments with over 100 million doses against serotypes 1, 4 and 8, representing sales of over 43 million euros.
CZ Veterinaria was founded in 1964 as CooperZeltia. In 1991, the initial company was divided up, and CooperZeltia Veterinaria came into existence; its name was changed to CZ Veterinaria in 1993.
Headed by Pedro Fernández Puentes, the veterinary company supplies its products to over 20 countries. With a state-of-the-art R+D+I department, its production to date has focused exclusively on veterinary medication.
AstraZeneca, which put its premises in Porriño on sale at the end of 2008, packages drugs used mainly to treat cardiac, intestinal and respiratory disorders.